Trial Profile
Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Feb 2022 Planned End Date changed from 1 Mar 2021 to 1 Jul 2024.
- 24 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2021 Results (n=21; between August 12, 2016 and December 13, 2018) assessing safety, toxicity and efficacy of nivolumab plus low-dose ipilimumab in patients with high-risk completely resected melanoma, published in the American Journal of Clinical Oncology.